You are here
Topiglan Study Fails To Meet Primary Endpoint
"While we are disappointed by these preliminary Topiglan data, we continue to advance our clinical studies of EcoNail(TM) and Opterone(TM)," said Robert J. DeLuccia, chief executive officer of MacroChem. "We plan in the weeks ahead to further analyze all of the Topiglan study data."
MacroChem currently has two other clinical programs underway. A dose- proportionality study of Opterone cream, an absorption-enhanced topical treatment for male testosterone deficiency, is ongoing. Patients are currently being dosed and results from that study are expected later this year. The Company has also initiated a Phase 1 study of EcoNail in patients with onychomycosis, a fungal infection of nails. Patient screening is nearly complete and data from this study are expected to be available by the end of the year.